Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 166

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 166
---
 policies and procedures. The risk of our being found in violation of these laws or other laws and regulations is further increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty associated with the violation, including civil and criminal penalties, damages and fines, we could be required to refund payments received by us, and we could lose the ability to bill for our tests, we could be prohibited from participating in public procurement, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results. Regardless, we will adopt policies and procedures to comply with these laws, which include internal reviews of our compliance with these laws in the ordinary course of our business. We plan to continue to expand operations abroad where we have limited operating experience and we may be subject to increased regulatory risks and local competition. If we are unsuccessful in efforts to expand internationally, our business may be harmed. Following the Closing, we plan to expand our product offering into two additional Latin American countries per year by leveraging our consortium model. This phased approach enables us, along with our partners, to thoroughly evaluate local opportunities, adapt our products to meet cultural and regulatory requirements, and effectively navigate varying market conditions. Our consortium strategy emphasizes partnerships with local laboratories and healthcare providers to ensure compliance with each country’s regulations while minimizing operational risks. To date, we have commenced market research and exploratory discussions with potential partners in key Latin American countries, including Mexico, Peru, Colombia, Chile, Ecuador, Uruguay, Dominican Republic, Costa Rica, and Panama, to align on regulatory requirements and market dynamics. Each country presents unique risks, primarily related to the adoption and growth of our products and services, as healthcare systems can vary significantly across the region. If there are issues with the expansion of our products in any of these countries, our operations abroad may be limited and our business may be adversely affected. Our regional processing hub in Mexico will expose us to Mexican regulations related to the handling, transport, and processing of biological samples. Non -compliancewith these regulations, or any changes to the regulatory environment, could result in